{"id":"NCT02308163","sponsor":"Astellas Pharma Inc","briefTitle":"A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs","officialTitle":"Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08-08","primaryCompletion":"2017-01-23","completion":"2017-11-22","firstPosted":"2014-12-04","resultsPosted":"2020-03-16","lastUpdate":"2024-10-28"},"enrollment":509,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Peficitinib","otherNames":["ASP015K"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Etanercept","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Peficitinib 100 mg","type":"EXPERIMENTAL"},{"label":"Peficitinib 150 mg","type":"EXPERIMENTAL"},{"label":"Etanercept","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study was to verify the superiority of ASP015K alone or in combination with disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an inadequate response to DMARDs","primaryOutcome":{"measure":"Percentage of Participants With an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12","timeFrame":"Baseline and Week 12/early termination (ET)","effectByArm":[{"arm":"Placebo","deltaMin":30.7,"sd":null},{"arm":"Peficitinib 100 mg","deltaMin":57.7,"sd":null},{"arm":"Peficitinib 150 mg","deltaMin":74.5,"sd":null},{"arm":"Etanercept","deltaMin":83.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":22},"locations":{"siteCount":153,"countries":["Japan","South Korea","Taiwan"]},"refs":{"pmids":["34429152","33929089","33068028","31350270"],"seeAlso":["https://astellasclinicalstudyresults.com/study.aspx?ID=335"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":101},"commonTop":["Nasopharyngitis","Injection site reaction","Rheumatoid arthritis","Blood creatine phosphokinase increased","Cough"]}}